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Objectives
To assess the sensitivity and specificity of self-reported osteoporosis compared with dual 
energy X-ray absorptiometry (DXA) defined osteoporosis, and to describe medication use 
among participants with the condition.
Methods
Data were obtained from a population-based longitudinal study and assessed for the 
prevalence of osteoporosis, falls, fractures and medication use. DXA scans were also 
undertaken.
Results
Overall 3.8% (95% confidence interval (CI) 3.2 to 4.5) of respondents and 8.8% (95% CI 7.5 to 
10.3) of those aged ≥ 50 years reported that they had been diagnosed with osteoporosis by a 
doctor. The sensitivity (those self-reporting osteoporosis and having low bone mineral density 
(BMD) on DXA) was low (22.7%), although the specificity was high (94.4%). Only 16.1% of 
those aged ≥ 50 years and with DXA-defined osteoporosis were taking bisphosphonates.
Conclusions
The sensitivity of self-reporting to identify osteoporosis is low. Anti-osteoporotic 
medications are an important part of osteoporosis treatment but opportunities to use 
appropriate medications were missed and inappropriate medications were used.
Article focus
 To assess the levels of sensitivity and spec-
ificity of dual energy X-ray absorptiometry
(DXA) measurements
 To compare DXA measurements with self-
reported osteoporosis
 To analyse the use of medication for
osteoporosis
Key messages
 The sensitivity of self-report is low
 Opportunities to use medications for
osteoporosis are missed
Strengths and limitations
 The analysis was conducted on a ran-
domly selected population cohort
 Over 1000 participants undertook a DXA
scan
 Only a single self-report question to
determine the prevalence of osteoporosis
was used
 T-scores were determined for total body
scan rather than the femoral neck
 A DXA scan was only conducted for those
aged ≥ 50 years
Introduction
Osteoporosis is a serious disease,1,2 a major
public health problem3-6 and an economic
burden on health systems.7-10 It is thought to
be common in the population, although true
population-wide prevalence estimates are
rare10 owing to the under-diagnosis of the
condition and the expense of undertaking
major epidemiological research to determine
prevalence estimates. The major differences
between estimates of prevalence arising from
self-reporting and clinical examination are of
concern. In an ageing society where health
resources are increasingly scarce, evidence-
based, population-wide, cheaply-assessed
estimates of this condition are required so
that effective interventions and appropriate
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preventive and treatment regimens can be implemented.
In an era where chronic diseases are important and health
resources are often determined on self-reported esti-
mates, it is important that the difference between self-
report and actual estimates are known and documented.
Increasingly, self-reported estimates of diabetes, asthma,
arthritis, mental health conditions and known risk factors
are used for policy and planning purposes.11,12 Osteo-
porosis is often overlooked as a priority chronic condition
worthy of financial and policy considerations because of
the lack of robust estimates.13
In addition, appropriate treatment of those with osteo-
porosis and adherence to treatment is of major concern.
As the population ages, the numbers of those with both
osteoporosis and fractures will increase. Recently, it has
been suggested that the current indications for subsi-
dised treatment of osteoporosis specified in the Australian
Pharmaceutical Benefits Scheme (PBS) ‘encourage over-
prescribing on the one hand, yet, on the other, deny
many patients with osteoporosis the treatment they
need’.14 However, Seeman et al15 in response to this letter
suggest that there is more likely to be an underutilisation
of drug therapy for osteoporosis rather than over- or inap-
propriate prescribing, and that ‘osteoporosis remains
underdiagnosed, underinvestigated and undertreated’.15
Various studies have demonstrated that higher mortality
occurs among community dwelling males and females
and those who have had a fracture, who do not use osteo-
porosis medications, vitamin D or calcium,16-20 thus indi-
cating the possible importance of these medications in
reducing mortality following fracture of the hip. Osteo-
porotic fractures also have a high economic and social
cost, placing a burden on the health care system and lim-
iting activities of daily living.21 The use of osteoporosis
medications such as calcium, vitamin D, hormone
replacement therapy (HRT) and bisphosphonates has also
been shown to improve the cost effectiveness of screen-
ing strategies.22 However, long-term adherence to drug
therapy does remain an issue.23
We aimed to investigate and compare the prevalence
and agreement of self-reported osteoporosis and dual
energy X-ray absorptiometry (DXA) diagnosed osteo-
penia and osteoporosis in a group of adults undergoing
screening DXA as part of a major population-based,
randomly-selected, cohort study (the North West
Adelaide Health Study (NWAHS)). A further aim was to
determine the use of relevant medications for those who
had osteoporosis or osteopenia (either self-reported or
DXA diagnosed).
Materials and Methods
Data were obtained from the NWAHS; a population based
biomedical cohort study established in 2000. This study
involves people living in the north-west region of
Adelaide, South Australia, randomly selected to partici-
pate and covers a broad range of socioeconomic areas. It
was designed to investigate the prevalence of chronic
conditions and health related risk factors, and to monitor
progression of diseases over time in order to help plan
health care provision in South Australia. The method-
ology has been described in detail elsewhere.24
Stage 2 of the study was conducted between 2004 and
2006, and comprised a Computer Assisted Telephone
Interview (CATI), a self-completed questionnaire and a
clinical assessment. Respondents completed surveys and a
clinic assessment that included measurement of blood
pressure, information assessing doctor-diagnosed condi-
tions (including osteoporosis, arthritis and cardiovascular
disease) and doctor-diagnosed and clinically assessed con-
ditions (diabetes and asthma), self-reported falls and
behavioural risk factors, health service utilisation and
demographics. The questionnaires were undertaken prior
to the clinic assessment. All medications that participants
were taking, including complementary and alternative
medicines, were recorded at the clinic visit. Those aged
≥ 50 years and attending the clinic were offered the oppor-
tunity to have a total body DXA scan. Respondents were
classified as having osteoporosis (T-score ≤ -2.5) or osteo-
penia (-1.0 > T-score > -2.5) using the World Health
Organization (WHO) definition of osteoporosis.25
Sample characteristics. The following data are
weighted, as described in the Statistical Analysis. A total
of 1718 males (49.1%) and 1782 females (50.9%) with a
mean age of 47.4 years (20 to 93) completed the CATI;
1600 males (49.1%) and 1659 females (50.9%) with a
mean age of 47.6 years (20 to 95) undertook the self-
completed questionnaire; and 1573 males (49.1%) and
1632 females (50.9%) with a mean age of 47.6 years
(20 to 95) undertook the clinical assessment.
This paper focuses on those aged ≥ 50 years. In this
group, there were 684 males (46.8%) and 779 females
(53.2%) (mean age 65.0 years) who completed the CATI;
642 males (46.9%) and 726 females (53.1%) (mean age
65.0 years) who completed the self-completed question-
naire; and 631 males (46.8%) and 717 females (53.2%)
(mean age 65.0 years) completing the clinical assessment. 
Of the 1463 subjects aged ≥ 50 years who completed
the telephone interview, 581 (39.7%) were aged 50 to
59 years, 383 (26.2%) were aged 60 to 69 years and
499 (34.1%) were aged ≥ 70 years. Of the 1348 subjects
aged ≥ 50 years who completed the clinical assessment,
540 (40.1%) were aged 50 to 59 years, 347 (25.7%) were
aged 60 to 69 years and 461 (34.2%) were aged ≥ 70 years.
Statistical analysis. Data were weighted to Census data by
region, age group, gender and probability of selection in
the household, to provide population representative esti-
mates, and all analyses are presented using weighted val-
ues. Data were analysed using SPSS version 19.0 (SPSS Inc.,
Chicago, Illinois). The study was approved by the institu-
tional ethics committees of the North West Adelaide Health
Service and all subjects gave written informed consent. A
p-value < 0.05 was considered statistically significant.
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Results
Overall, 79.1% (n = 1066) of participants aged ≥ 50 years
underwent DXA scanning. The remainder did not
undergo DXA scanning primarily due to scheduling
issues, although females (54.7%, n = 583) were signifi-
cantly more likely to undergo a DXA scan compared with
males (45.3%, n = 483) (Pearson chi-squared test = 4.79,
p = 0.03), and those aged ≥ 70 years (31.9%, n = 340)
were less likely to undergo a scan compared with those
aged 50 to 59 years (41.1%, n = 438) and those aged 60 to
69 years (26.9%, n = 287), as were those aged 60 to
69 years compared with those aged 50 to 59 years and
those aged ≥ 70 years (Pearson chi-squared test = 11.82,
p = 0.003). The overall prevalence of DXA-diagnosed
osteopenia or osteoporosis was 18.7% (95% confidence
interval (CI) 16.6 to 20.9) (Table I). Of the participants
who underwent a DXA scan, 3.6% (95% CI 2.6 to 4.9)
had osteoporosis (a T-score ≤ -2.5) and 15.1% (95%
CI 13.2 to 17.1) were osteopenic (-1.0 > T-score > -2.5)
(Table I).
The overall prevalence of self-reported osteoporosis in
the NWAHS was 3.8% (n = 133; 95% CI 3.2% to 4.5%)
while the prevalence of self-reported osteoporosis
amongst participants aged ≥ 50 years was 8.8% (n = 129;
95% CI 7.5 to 10.3). This was higher in female participants
at 14.4% (n = 112; 95% CI 12.2 to 17.0) than in men at
2.5% (n = 17; 95% CI 1.6 to 3.7) (p < 0.001) and among
those aged ≥ 70 years at 15.3% (n = 76; 95% CI 12.4 to
18.7). The prevalence was statistically significantly lower,
compared with the other age groups, in those 50 to
59 years (3.6%; n = 21; 95% CI 2.4 to 5.4) (p < 0.001). The
prevalence in those aged 60 to 69 years was 8.3% (n = 32;
95% CI 6.2 to 11.0).
Table II highlights the poor agreement between self-
reported and DXA scores for osteoporosis for those respon-
dents aged ≥ 50 years who provided both of these mea-
sures. As the questionnaires were undertaken prior to the
DXA scan, the self-report results were not influenced by
the clinical assessment. Over half of the participants who
reported that they had been told by a doctor that they had
osteoporosis, had normal bone mineral density (BMD) on
DXA (52.9%; 95% 43.4 to 62.1), with the remaining 47.1%
having abnormal BMD (either osteopenia (38.1%) or
osteoporosis (9.0%)). Of the participants with DXA-
diagnosed osteopenia or osteoporosis (n = 192), 22.7%
reported that they had been diagnosed with osteoporosis
(n = 44; 95% CI 17.8 to 28.6), resulting in the remaining
77.3% (95% 71.4 to 82.2) being classified as newly diag-
nosed or undiagnosed osteopenia or osteoporosis.
The use of self-reported osteoporosis in epidemio-
logical or population studies as a screening tool for DXA-
diagnosed osteopenia or osteoporosis was assessed, and
the sensitivity, specificity, positive and negative predictive
values were calculated. The sensitivity was 22.7%, speci-
ficity 94.4%, positive predictive value 47.1%, and nega-
tive predictive value 84.8%. This shows that the positive
predictive value of having low BMD on DXA in people
who self-report that they have osteoporosis is poor
(47.1%), but the proportion of people with no self-
reported osteoporosis who have normal DXA results is
high (specificity of 94.4%).
In terms of medication use, of the respondents who
self-reported that they had osteoporosis, 43.9% (n = 50)
used oral bisphosphonates and a small proportion of
respondents who stated that they did not have osteo-
porosis also took bisphosphonates (0.4%; n = 13), indicat-
ing a lack of understanding as to why they were taking
particular medications. Of those who self-reported that
they had osteoporosis, the most frequently used bisphos-
phonate was alendronate (72.2%; n = 36). There were
also three respondents (2.4%) who stated that they had
osteoporosis and were taking raloxifene. No other bone
specific drugs such as zolendronate or strontium ranelate
(available on the PBS since 2009 and 2007, respectively)
were used. Finally, there were nine respondents (7.8%)
who said they had been told that they had osteoporosis
and took a form of hormone replacement therapy (HRT).
Of the participants with DXA-defined osteoporosis or
osteopenia, 16.1% (n = 21) and 13.3% (n = 6) were taking
bisphosphonates, respectively, as were 3.1% (n = 27) of
those with a normal DXA scan.
However, among all respondents who stated that they
had osteoporosis and were taking a bisphosphonate, only
12.1% (n = 6) also took both calcium and vitamin D
(including calcitriol). Of those with osteoporosis and
Table I. Prevalence of dual energy X-ray absorptiometry (DXA)-
diagnosed osteoporosis and osteopenia in patients aged
≥ 50 years (CI, confidence interval)
Number* Prevalence (%)(95% CI)
Normal DXA scan 867 81.3 (79.1 to 83.4)
Osteopenic 161 15.1 (13.2 to 17.1)
Osteoporosis 38 3.6 (2.6 to 4.9)
Total 1066 100.0
* the weighting of data can result in rounding discrepancies or
totals not adding
Table II. Self-reported versus dual energy X-ray absorptiometry (DXA)-






n* Prevalence (%) (95% CI) n
* Prevalence (%) 
(95% CI)
Normal DXA 825 84.8 (82.5 to 86.8) 49 52.9 (43.4 to 62.1)
Osteopenia 120 12.4 (10.6 to 14.4) 35 38.1 (29.1 to 48.6)
Osteoporosis 28 2.9 (2.0 to 4.1) 8 9.0 (5.0 to 15.7)
Total 973 100.0 93 100.0
* the weighting of data can result in rounding discrepancies or totals not
adding. Includes only those respondents who completed both the tele-
phone survey and undertook a DXA scan
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taking a bisphosphonate, 31.4% (n = 16) were also taking
proton pump inhibitors.
Of all participants aged ≥ 50 years, 2.9% (n = 38;
95% CI 2.1 to 3.9) were on oral steroids and eight of these
(21.4% (95% CI 10.6 to 38.5)) were also taking bisphos-
phonates. Of those on steroids, 0.8% (n = 1) and 22.2%
(n = 6) had DXA-defined osteoporosis and osteopenia
respectively and 37.7% (n = 2) of those who had took
steroids and had undertaken a DXA scan were also taking
bisphosphonates.
Among respondents who had a fracture as a result of a
fall from a standing height or less in the last five years,
16.8% (n = 33; 95% CI 11.9 to 23.2) had been told by a
doctor that they had osteoporosis. Of these respondents,
59.0% (n = 9; 95% CI 41.8 to 74.2) were on bisphos-
phonates and 12.0% (n = 4; 95% CI 4.6 to 27.6) were cur-
rently on benzodiazepines. When considering those aged
≥ 50 years, only 7.8% (n = 7) of those who had a fall had
a bone density in the osteoporotic range. Of those taking
benzodiazepines 3.8% (n = 2) and 14.0% (n = 8) respec-
tively had DXA-defined osteoporosis or osteopenia.
Discussion
Our results show that self-reported osteoporosis is poorly
predictive of DXA-diagnosed osteopenia or osteoporosis,
with a positive predictive value no better than chance at
47%. Of those participants who had stated that they had
been diagnosed by their doctor as having osteoporosis,
9.0% had DXA-defined osteoporosis, further suggesting
that self-reported medically diagnosed osteoporosis is
likely to lack accuracy in a population study such as this.
In addition, our results also show that even though med-
ication is an important part of osteoporosis treatment
and fracture prevention, for those whose doctor had told
them they had osteoporosis, and those who had suffered
a minimal trauma fracture, opportunities to use appropri-
ate medications were missed and inappropriate medica-
tions were used.
In terms of the marked differences in self-reported
and clinically diagnosed osteoporosis, using these data
we are unable to determine why 53% of those over
50 years of age who had self-reported osteoporosis but
normal BMD on DXA thought they had osteoporosis.
Women particularly may have been told by a health
professional that they had osteoporosis but never had a
DXA in order to confirm or refute this possibility.
Another possible reason is that the terms osteoporosis
and osteoarthritis are often confused in lay terminol-
ogy without the distinction between the two disease
processes being recognised. As such, persons report-
ing that they have osteoporosis may instead have
osteoarthritis. Interviewing of participants would be
required to determine what the term osteoporosis
meant to them individually. These data also showed
that few men with osteoporosis are diagnosed (the
small number made analysis by gender inappropriate),
which supports data in the literature showing that
while osteoporosis is under-diagnosed even in women,
the under-diagnosis is more marked in men.26
Our study also demonstrates that, in this population-
based sample, only a minority of participants with min-
imal trauma fractures (7.8%) were osteoporotic on DXA
scan. This is consistent with previous data from the
Study of Osteoporotic Fractures data set that demon-
strated the proportion of fractures attributable to osteo-
porosis was modest (10% to 44% depending on the
fracture), using the same commonly used definition of
osteoporosis (a T-score ≤ -2.5). These results demon-
strate that other interventions are required beyond
pharmacological treatment for bone loss, such as pre-
vention of falls and other fracture risk factors.27 In our
study, the majority of participants (59.0%) who had a
minimal trauma fracture were prescribed bisphos-
phonates. In contrast, 16.1% of those aged 50 years and
over, with DXA-defined osteoporosis, were on bisphos-
phonates.
The use of bisphosphonates in this study appeared to
be consistent with the PBS-subsidised indications at the
time of the study although it is of note that among
respondents who stated that they did not have osteo-
porosis, 0.4% took bisphosphonates indicating a lack of
understanding as to why they were taking particular
medications. Since this study was completed, the PBS
indications for use of bisphosphonates in Australia have
broadened to include not only those who have
sustained fracture, but also those ≥ 70 years of age with
BMD T-score < -3.0 and those using long-term high-
dose corticosteroid therapy with BMD T-score of -1.5 or
less.28,29
Although there was a low rate of co-prescription of cal-
cium and vitamin D with bisphosphonates in the current
study, subsequent changes to the presentation of
bisphosphonates now offer vitamin D and calcium sup-
plementation with the bisphosphonate. This single pre-
scription is likely to increase the rate of co-prescribing of
bisphosphonates with vitamin D and calcium, in line with
current recommendations.
The co-prescription of benzodiazepines in partici-
pants with fractures, self-reported falls and osteo-
porosis is troubling as benzodiazepines have been
demonstrated to both increase the risk of falls and frac-
ture in the elderly.23,30 Almost a third of participants
using bisphosphonates were also using a proton pump
inhibitor, suggesting co-morbid gastro-oesophageal
reflux or peptic ulcer disease and there may also be an
effect on calcium absorption. Although caution needs
to be taken with the use of bisphosphonates in patients
with active upper gastrointestinal problems, such as
oesophageal diseases, gastritis or ulcers,31 results from
the Fracture Intervention Trial demonstrated no
increased risk of upper gastrointestinal events in
patients taking alendronate compared to placebo.32
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Although anti-osteoporotic medication is an impor-
tant part of osteoporosis treatment and fracture preven-
tion, opportunities to use appropriate osteoprotective
medications (calcium, HRT, selective oestrogen receptor
modulators and vitamin D) were missed and inappropri-
ate medications such as benzodiazepines were used for
those at risk of osteoporotic fracture.
The strengths of this study are that analysis was con-
ducted on a randomly selected population cohort and
over 1000 participants undertook a DXA scan. All DXA
results were provided to general practitioners and/or
patients if requested and while this is not an intervention
cohort, follow-up assessments will determine if self-report
and DXA information more closely align. The weaknesses
of the study are using a single self-report question to deter-
mine the prevalence of osteoporosis rather than a self-
assessment tool, that total body scan T-scores were deter-
mined rather than femoral neck, that the DXA scan was
only undertaken for those aged ≥ 50 years, and that due to
the cross-sectional nature of the study, there is an inability
to examine effects on BMD over time due to medication
use. There is also the issue of the health literacy level of par-
ticipants; in that there was no assessment of the under-
standing of the term osteoporosis among those surveyed
that may also impact on the ability to accurately self-report
the existence of osteoporosis. However, despite the limita-
tions, the results have an important message particularly
with regard to understanding the condition of osteo-
porosis and the use of medications.
In conclusion, this study highlights that the sensitivity
and positive predictive values for self-reporting to identify
osteoporosis are low and there is mismatch between self-
reporting and DXA diagnosis of osteoporosis, highlight-
ing the need for better means of identifying osteoporosis
at the population level. While the identification of osteo-
porosis in the population is a challenge, addressing
health literacy and communication in relation to osteo-
porosis may be of benefit. The study also highlights that
opportunities to provide osteoprotective medications are
often missed and inappropriate medications are sup-
plied. This indicates that prescribing practices need to be
more carefully examined in order to assist in the preven-
tion of osteoporosis and associated fractures.
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